Results 291 to 300 of about 917,012 (395)

Successful Lebrikizumab Therapy in Two Patients With Atopic Dermatitis Resistant to Multiple Therapies

JEADV Clinical Practice, EarlyView.
ABSTRACT The treatment landscape for moderate‐to‐severe atopic dermatitis (AD) has evolved significantly with the introduction of novel targeted therapies addressing specific pathogenic mechanisms of the disease. Despite this therapeutic revolution, a proportion of patients experience intolerance and/or inadequate response to multiple lines of ...
Elena Ippoliti, Niccolò Gori, Benedetta Ambrosio, Giulia Coscarella, Maria Vittoria Cannizzaro, Ketty Peris   +5 more
wiley   +1 more source

Exogenous Testosterone and Estrogen Blocker-Associated Venous Thrombosis Presenting With Acute Aphasia: A Case Report. [PDF]

Cureus
Weissman B, Chowdhury S, Saju S, Pusatier M.   +3 more
europepmc   +1 more source

Guideline on aspects of cancer‐related venous thrombosis

British Journal of Haematology, 2015
H. Watson, D. Keeling, M. Laffan, R. Tait, M. Makris   +4 more
semanticscholar   +1 more source

Venous thrombosis and embolism [PDF]

The Journal of Bone and Joint Surgery. British volume, 1981
openaire   +3 more sources

Unilateral Upper Limb Lymphedema After Microwave Thermolysis Treatment for Axillary Hyperhidrosis

JEADV Clinical Practice, EarlyView.
ABSTRACT Microwave thermolysis (MiraDry) is an approved, nonsurgical treatment for axillary hyperhidrosis. We report a case of unilateral lymphedema of the upper limb in a 45‐year‐old male patient treated for axillary hyperhidrosis with the MiraDry device.
Emanuela Micu, Natalja Jacobsson
wiley   +1 more source

Clinical outcomes of endovascular interventions for cerebral venous thrombosis in Japan: a nationwide retrospective study. [PDF]

Stroke Vasc Neurol
Senda A, Suginaka H, Morishita K, Fushimi K.   +3 more
europepmc   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Spontaneous Intracranial Hypotension Complicated by Bilateral Cerebral Venous Thrombosis in an Older Adult: A Case Report. [PDF]

Cureus
Haque MZ, Arunachalam G, Ghosh R.
europepmc   +1 more source

Complications of liver transplantation [PDF]

, 1987
Bronsther, OL, Esquivel, CO, Gordon, RD, Iwatsuki, S, Lerut, JP, Makowka, L, Starzl, TE   +6 more
core  

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source